Breakthrough cancer therapy developed at Penn receives 2nd FDA approval

The Food and Drug Administration on Tuesday approved a second indication for a revolutionary cancer therapy initially developed by researchers at the University of Pennsylvania's Abramson Cancer Center. The FDA cleared Kymriah, a personalized cellular therapy marketed by Novartis, for use in patients with advanced non-Hodgkin's lymphoma. The FDA specifically approved Kymriah for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible fo r…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news

Related Links:

In conclusion, these results provide new data validating HDACis and, especially, panobinostat as a novel anti-cancer therapy for veterinary applications, while contributing to comparative oncology. PMID: 29983882 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
The Food and Drug Administration on Tuesday approved a second indication for a revolutionary cancer therapy initially developed by researchers at the University of Pennsylvania's Abramson Cancer Center. The FDA cleared Kymriah, a personalized cellular therapy marketed by Novartis, for use in patients with advanced non-Hodgkin's lymphoma. The FDA specifically approved Kymriah for the treatment of certain adult patients with relapsed or refractory diffuse large B-cell lymphoma. The American Cancer …
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Till 1998, a little was known about alternative forms of regulated cell death beside apoptosis. In present scenario, accumulating evidences suggest a form of programmed necrosis called Necroptosis which can be induced by various external stimuli including anticancer drugs, ionizing radiation, photodynamic therapy in the form of death domain receptor (DR) engagement by their respective ligands, TNF-alpha, Fas ligand (FasL) and TRAIL, under apoptosis deficient condition (caspase inhibitor),etc. receptor interacting protein-1 (RIP-1), a death domain containing kinase is the key molecule in necroptotic cell death pathway. On i...
Source: Oncology Reviews - Category: Cancer & Oncology Source Type: research
Authors: Peng X, Shi J, Sun W, Ruan X, Guo Y, Zhao L, Wang J, Li B Abstract IL-6 is critical for tumorigenesis. However, previous studies on the association of IL-6 promoter polymorphisms with predisposition to different cancer types are somewhat contradictory. Therefore, we performed this meta-analysis regarding the relationship between IL-6 promoter single nucleotide polymorphisms and cancer susceptibility and prognosis. Up to April 2017, 97 original publications were identified covering three IL-6 promoter SNPs. Our results showed statistically significant association between IL-6 promoter and cancer risk and pr...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
ConclusionWhile cancer therapies are known to increase the risk of CVD, this study additionally shows that CVD risk varies by sociodemographic factors.Implications for cancer survivorsThe identification and mitigation of CVD risk factors in these subgroups may improve long-term patient outcomes.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
Authors: Belay Y, Yirdaw K, Enawgaw B Abstract Tumor lysis syndrome is a metabolic complication that may follow the initiation of cancer therapy. It commonly occurs in hematological malignant patients particularly non-Hodgkin's lymphoma and acute leukemia due to chemotherapy or spontaneously. It is characterized by a biochemical abnormality such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia and its clinical outcome is directly related to these biochemical abnormalities. Prevention and treatment of tumor lysis syndrome depend on immediate recognition of patients at risk. Therefore, identifying ...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
CONCLUSION: Poor response against pneumococcal vaccines increases the susceptibility of respiratory diseases in these patients. In patients with NHL treated with RTX, the benefits achieved with IVIg replacement for the control of recurrent infectious diseases is of paramount importance. Clinicians dealing with monoclonal antibodies against cancer therapy, especially RTX, should be aware of the increasing risks for symptomatic induced hypogammaglobulinemia and respiratory infections. PMID: 29094629 [PubMed - as supplied by publisher]
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
We examined the combination of the FDA-approved drug ingenol-3-angelate (PEP005) with epigenetic drugs as a rational therapeutic approach for KSHV-mediated malignancies. JQ1, a bromodomain and extra terminal (BET) protein inhibitor, in combination with PEP005, not only robustly induced KSHV lytic replication, but also inhibited IL6 production from PEL cells. Using the dosages of these agents that were found to be effective in reactivating HIV (as a means to clear latent virus with highly active antiretroviral therapy), we were able to inhibit PEL growth in vitro and delay tumor growth in a PEL xenograft tumor model. KSHV r...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Models and Technologies Source Type: research
In this study, we show that ABBV-075 efficiently triggers apoptosis in acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells. Apoptosis induced by ABBV-075 was mediated in part by modulation of the intrinsic apoptotic pathway, exhibiting synergy with the BCL-2 inhibitor venetoclax in preclinical models of AML. In germinal center diffuse large B-cell lymphoma, BCL-2 levels or venetoclax sensitivity predicted the apoptotic response to ABBV-075 treatment. In vivo combination studies uncovered surprising benefits of low doses of ABBV-075 coupled with bortezomib and azacitidine treatment, despite the la...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Therapeutics, Targets, and Chemical Biology Source Type: research
Human REV7 (also known as MAD2L2 and MAD2B) is involved in DNA repair, cell cycle regulation, gene transcription and carcinogenesis, and is a key protein in translesion DNA synthesis. Here, we present our study to evaluate the significance of REV7 expression in human malignancy and its possibility to be a molecular target for cancer therapy. REV7 expression was assessed in epithelial ovarian cancer (EOC) and diffuse large B-cell lymphoma (DLBCL) by immunohistochemical staining. REV7 expression was detected in the majority of EOCs (92.0%) with especially high levels of expression frequently observed in ovarian clear cell ca...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Exploiting Repair Defects in the Tumor Microenvironment: Poster Presentations - Proffered Abstracts Source Type: research
More News: American Health | Cancer | Cancer & Oncology | Cancer Therapy | Food and Drug Administration (FDA) | Health Management | Lymphoma | Non-Hodgkin's Lymphoma | University of Pennsylvania